Re: Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024
posted on
Sep 25, 2024 04:25PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Settle down there, fuzzy.
Koo